News – Page 896 – Endpoints News

In a first, FDA green-lights use of a Chinese built cancer therapy — and more are coming

6 years ago

Amarin emerges from an expert panel review with a clear endorsement for Vascepa and high odds of success when the FDA ...

6 years ago

BioMarin breaks out positive PhII achondroplasia data; Thermo Fisher opens 'customer solutions' facility in China

6 years ago

What does $62B buy you these days? A lot, says Takeda execs as the pharma player promises a blockbuster R&D future

6 years ago

Sarepta picks up a slate of preclinical gene therapy programs, seeding new StrideBio deal with $48M upfront

6 years ago

Shorts galore: Muddy Waters sees slide for PeptiDream, tweets concerns about FibroGen's new data

6 years ago

Pincer movement: California biotech gets $35M to suffocate cancer in coordinated attack

6 years ago

Little biotech’s stock flatlines as its followup attempt at a depression drug trial win ends in another defeat

6 years ago

Allergan enlists Exicure in search of hair loss drugs with $25M upfront, doubling down on area dear to AbbVie

6 years ago

AstraZeneca, Merck win red carpet treatment at the FDA as a 3-time loser seeks speedy OK for rare tumors

6 years ago

FDA panel largely opposes expanding use of Lilly, Boehringer's SGLT2 inhibitor to type 1 diabetics

6 years ago

Bayer bets up to $100M on exploring new biomolecular condensate terrain with a biotech upstart

6 years ago

Investors could emerge from Neil Woodford debacle with £1B loss, internal analysis reveals

6 years ago

Seattle and Daiichi Sankyo at each other's throats; UC Berkeley, UCSF and the University of Washington launch Weill ...

6 years ago

FDA slaps a hold on an AML trial as Marker scraps a failing ovarian cancer program, sinking shares

6 years ago

Takeda doubles down on Finch's microbiome insights, signing up for a second project in Crohn's disease

6 years ago

GSK's asthma biologic Nucala scores in rare blood disorder study

6 years ago

FDA’s Project Orbis may expand to Singapore and Switzerland

6 years ago

Eli Lilly-backed biotech grabs $100M to dispatch antibody-oligonucleotide conjugates after muscular dystrophy

6 years ago

Ahead of FDA decision on BTK drug, Amgen-partnered BeiGene is one step closer to China OK for PD-1

6 years ago

Merck buys a fledgling neurodegenerative biotech spawned by an old GSK discovery alliance. What’s up with that?

6 years ago

AstraZeneca sets stage for marketing application with promising pivotal lupus drug data

6 years ago

Kiadis abandons lead PhIII program, shifts focus to natural killer cells

6 years ago

Merck shutters French research site in a reorganization aimed at eliminating more than 200 jobs

6 years ago

First page Previous page 893 894 895896897 898 899 Next page Last page